Navigation Links
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Date:3/28/2013

MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreement with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of EPI-743 and EPI-589 in Japan. Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support. In addition, Edison will be eligible to receive $10-35 million in development milestones per indication and up to $460M in commercial milestone payments as well as royalties on commercial sales.

The initial scope of the transaction includes both pediatric orphan inherited mitochondrial and adult central nervous system diseases. Under the terms of the agreement, DSP will undertake activities required for development, approval, and commercialization of EPI-743 in Japan. The work will initially focus on orphan pediatric mitochondrial disease. Edison will retain 100% ownership and direct all research, clinical, and commercial development of EPI-743 and EPI-589 outside of Japan.

In addition, the parties will collaborate on the research and development of EPI-589 with a focus on adult central nervous system disease. This collaboration is based upon the emerging body of data implicating redox and mitochondrial dysfunction as a root cause of neurologic disorders.

Edison's translational platform is based on redox biochemistry.  It bridges key learnings derived from genetically confirmed pediatric rare mitochondrial disease to adult central nervous system disorders where redox and mitochondrial dysfunction are likely to also play a cr
'/>"/>

SOURCE Edison Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
9. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
10. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/pw67sw/xray_market ) has announced ... Size, Share, Growth, Trends and Forecast 2014 - 2022" ... held the largest share of 34.6% of the ... Pacific and Europe . ... the U.S. and Canada that have ...
(Date:5/21/2015)... Kalifornien, und KOPENHAGEN, Dänemark, 21. Mai 2015 ... ein Weltmarktführer bei der klinischen und kommerziellen ... man werde im Rahmen der weltweiten Kapazitätserweiterungsstrategie ... 14.000 Liter Produktionskapazität erweitern. Logo ... erhalten durch das innovative Einweg Bioreactor 6Pack ...
(Date:5/21/2015)... BETHESDA, Md. , May 21, 2015 /PRNewswire-USNewswire/ ... an open innovation competition designed to bring promising ... the Heritage Provider Network (HPN) in collaboration with ... Center for Advancing Innovation (CAI).  The winning teams ... models and live pitches and will move forward ...
Breaking Medicine Technology:X-Ray Market: Global Industry Analysis 2014 - 2022 2CMC Biologics erweitert GMP-Produktionskapazität in Europa 2CMC Biologics erweitert GMP-Produktionskapazität in Europa 3Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 2Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 3Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 4
... , TOLOCHENAZ, Switzerland , March 23, 2010 , ... , ... ... ...
... DUBLIN , March 23, 2010 ... product that allows life science companies to review,validate and ... collaboration across the process. PRISYM Medica is a,web-based solution ... and approve labelling on a variety of products, from ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9PRISYM ID's Medica Greatly Simplifies FDA and MHRA Compliance 2PRISYM ID's Medica Greatly Simplifies FDA and MHRA Compliance 3PRISYM ID's Medica Greatly Simplifies FDA and MHRA Compliance 4
(Date:5/22/2015)... Maine (PRWEB) May 22, 2015 ... single-use swabs for the medical, diagnostic, environmental, and ... entire line of products in the US. At ... their operations outside the US, Puritan remains committed ... products at their Guilford, Maine facility. , Since ...
(Date:5/22/2015)... May 22, 2015 Pro3rd Impression ... designed exclusively for Final Cut Pro X. Pro3rd Impression's ... design. , Intuitive on-screen-controls allow users to customize ... Reflections, colors, layouts, and much more can be edited ... , Pro3rd Impression comes packed with 30 ...
(Date:5/21/2015)... TAMPA, Fla. (PRWEB) May 21, 2015 WellCare ... Health Plan has been selected by the Florida Healthy Kids ... children 5-18 years of age, as part of the Florida ... begin on Oct. 1, 2015, and may be extended for ... an opportunity to serve children in the FHK program who ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 ChiliPad ... surface temperature of each side of the bed so ... users on either side of the bed can pick ... helping them fall asleep faster and stay asleep longer. ... with water to regulate the temperature which produces a ...
(Date:5/21/2015)... The ThedaCare Center for Healthcare Value welcomes long-time faculty ... Barnas is based in Appleton to support operations as she ... and support Center teams that are working to help healthcare ... experience , Making quality more transparent , ... , The Center is excited to bring Barnas’s knowledge of ...
Breaking Medicine News(10 mins):Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2Health News:ChiliPad, a Dual-Zone Temperature-Controlled Mattress Pad, Promotes Better Sleep, Health Benefits, and Saves on Cooling Costs in Upcoming Hot Summer Weather 2Health News:ChiliPad, a Dual-Zone Temperature-Controlled Mattress Pad, Promotes Better Sleep, Health Benefits, and Saves on Cooling Costs in Upcoming Hot Summer Weather 3Health News:Kim Barnas joins ThedaCare Center for Healthcare Value 2
... 30 (HealthDay News) --,A physically active lifestyle may help protect ... Glaucoma, a leading cause of blindness, typically develops when fluid ... In this study, researchers looked at the association between ... aged 48 to 90 in Britain. The participants were evaluated ...
... specific, exercise-related responses can help physicians determine who may ... (SHAI), according to a study conducted by researchers in ... a drug frequently prescribed to prevent altitude illness, can ... The findings were published online ahead of the ...
... News) -- Many Alzheimer,s patients who take cholinesterase inhibitors ... counter the effects of those Alzheimer,s medications, a new ... inhibitors such as Aricept (donepezil) have a modest impact ... disease, noted the researchers at the Group Health Research ...
... New York University College of Nursing (NYUCN) received ... Resources & Services Administration (HRSA) to research "Midwifery: ... Principal Investigator Ann Kurth notes that Nurse-Midwives state ... practice is the lack of experience in clinical ...
... News) -- Surgery to remove all or part of ... to reduce snoring and other symptoms of obstructive sleep ... symptoms in patients with obstructive sleep apnea before and ... obstructive sleep apnea include snoring, disrupted breathing during sleep ...
... antibiotics, which are active against a whole range of ... long time. Comparably versatile drugs to treat viral diseases, ... new approach, research teams led by Dr. Albrecht von ... the University of Bonn have identified a compound that ...
Cached Medicine News:Health News:Glaucoma Experts Eye Benefits of Exercise 2Health News:Researchers identify potential risk factors for severe altitude sickness 2Health News:Researchers identify potential risk factors for severe altitude sickness 3Health News:Researchers identify potential risk factors for severe altitude sickness 4Health News:Some People With Alzheimer's Take Conflicting Drugs 2Health News:NYUCN receives $1 million HRSA grant to incorporate primary care into nurse-midwives' education 2Health News:Thyroid Surgery Linked to Improved Sleep Apnea Symptoms 2Health News:Novel strategy stymies SARS et al. 2Health News:Novel strategy stymies SARS et al. 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: